GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (WBO:ABT) » Definitions » Cash Flow from Operations

Abbott Laboratories (WBO:ABT) Cash Flow from Operations : €7,987 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Abbott Laboratories Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2024, Abbott Laboratories's Net Income From Continuing Operations was €1,483 Mil. Its Depreciation, Depletion and Amortization was €722 Mil. Its Change In Working Capital was €147 Mil. Its cash flow from deferred tax was €0 Mil. Its Cash from Discontinued Operating Activities was €0 Mil. Its Asset Impairment Charge was €0 Mil. Its Stock Based Compensation was €105 Mil. And its Cash Flow from Others was €-20 Mil. In all, Abbott Laboratories's Cash Flow from Operations for the three months ended in Sep. 2024 was €2,437 Mil.


Abbott Laboratories Cash Flow from Operations Historical Data

The historical data trend for Abbott Laboratories's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Cash Flow from Operations Chart

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,522.40 6,494.62 9,321.71 9,044.46 6,658.34

Abbott Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,758.75 2,785.85 943.00 1,820.84 2,437.21

Abbott Laboratories Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Abbott Laboratories's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Abbott Laboratories's Cash Flow from Operations for the quarter that ended in Sep. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €7,987 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbott Laboratories  (WBO:ABT) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Abbott Laboratories's net income from continuing operations for the three months ended in Sep. 2024 was €1,483 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Abbott Laboratories's depreciation, depletion and amortization for the three months ended in Sep. 2024 was €722 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Abbott Laboratories's change in working capital for the three months ended in Sep. 2024 was €147 Mil. It means Abbott Laboratories's working capital increased by €147 Mil from Jun. 2024 to Sep. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Abbott Laboratories's cash flow from deferred tax for the three months ended in Sep. 2024 was €0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Abbott Laboratories's cash from discontinued operating Activities for the three months ended in Sep. 2024 was €0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Abbott Laboratories's asset impairment charge for the three months ended in Sep. 2024 was €0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Abbott Laboratories's stock based compensation for the three months ended in Sep. 2024 was €105 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Abbott Laboratories's cash flow from others for the three months ended in Sep. 2024 was €-20 Mil.


Abbott Laboratories Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.